This is one example of how we’ve seen pharma shift towards being more patient-centric as these apps allow the public the be more in control of their health and engage better with companies on patient platforms.įurther to this, the current pandemic has transformed the industry at all levels, leaving many questions, such as, ' Could remote decentralised clinical trials be the future?' Globalisation of pharma As we entered the 2010s, we witnessed products for drugs being sourced and manufactured internationally, then sold on a global market platform – this globalisation is a first for the pharmaceuticals industry. The industry hasn’t missed out on tapping into the app market – according to Deloitte, from 2013 to 2016 pharma companies tripled the number of apps they developed. Using this new information to create a revived business model means that companies can produce drugs faster than ever before while artificial intelligence has enabled us to improve a patient’s responsiveness to drugs. Predictive analytics, big data analytics and AI-based tools have given companies the tools they need to redesign their business processes. Here’s an overview of an exciting decade in pharmaceuticals.ĭigital is revolutionising pharmaceuticals Like every industry, pharmaceuticals has been transformed by digital technologies. These factors are the key driving forces behind the growth of the industry over the last decade and we only expect this to continue, which means the future is bright for clinical research professionals.
As for the public’s involvement, they’re becoming increasingly aware of the drugs they’re being prescribed which has pushed pharma companies to develop a more personalised level of treatment in the form of precision medicine. However, the US has maintained its majority share of the market and oncology remains the most valuable branch of therapy.
The pharmaceuticals industry has been revolutionised over the last decade due to advances in technology and globalisation – and with it have come changes in clinical research.
0 kommentar(er)
